MESO MESOBLAST LTD IFRS
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1345099 · Fiscal year ends 06/30
Financial factors as of 2025-06-30 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2023Q4*2023-06-30 | 2023Q32023-03-31 | 2023Q22022-12-31 | 2023Q12022-09-30 | 2022Q4*2022-06-30 | 2022Q32022-03-31 | 2022Q22021-12-31 | 2022Q12021-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.14M | $1.94M | $2.13M | $1.50M | $2.22M | $2.01M | $2.38M | $3.59M |
| R&D expense | $6.69M | $7.07M | $7.68M | $5.74M | $5.04M | $8.25M | $10.20M | $9.33M |
| Interest expense | $5.09M | $4.90M | $4.90M | $4.55M | $4.41M | $4.30M | $4.06M | $4.14M |
| Pretax income | -$21.96M | -$18.65M | -$24.56M | -$16.94M | -$21.51M | -$21.35M | -$26.02M | -$22.71M |
| Income tax | -$40,000 | -$46,000 | -$71,000 | -$55,000 | -$52,000 | -$45,000 | -$80,000 | -$62,000 |
| Net income | -$21.92M | -$18.60M | -$24.49M | -$16.88M | -$21.45M | -$21.30M | -$25.95M | -$22.64M |
| EPS (basic) | — | -0.03 | -0.03 | -0.02 | — | -0.03 | -0.04 | -0.03 |
| EPS (diluted) | — | -0.03 | -0.03 | -0.02 | — | -0.03 | -0.04 | -0.03 |
| Weighted avg. shares (diluted) | — | 736.58M | 736.58M | 696.07M | — | 649.56M | 648.10M | 648.05M |
| Balance sheet | ||||||||
| Cash & equivalents | $71.32M | $48.80M | $67.62M | $85.50M | $60.45M | $76.76M | $94.85M | $115.96M |
| Receivables | $7.00M | $8.39M | $5.12M | $3.86M | $4.40M | $5.63M | $6.05M | $5.63M |
| Current assets | $81.66M | $61.37M | $78.13M | $92.96M | $69.84M | $88.13M | $108.80M | $126.22M |
| PP&E, netmay include right-of-use assets (IFRS) | $1.36M | $1.48M | $1.56M | $1.79M | $2.04M | $2.24M | $2.47M | $2.75M |
| Total assets | $669.41M | $650.44M | $668.06M | $684.50M | $662.14M | $681.69M | $704.44M | $721.82M |
| Current liabilities | $41.98M | $53.92M | $54.58M | $48.80M | $51.37M | $52.19M | $57.95M | $92.90M |
| Short-term debt | $5.95M | $7.31M | $5.94M | $5.49M | $5.02M | $5.52M | $5.20M | $53.85M |
| Long-term debt | $102.81M | $99.04M | $96.98M | $94.19M | $91.62M | $88.65M | $86.54M | $42.65M |
| Total debt | $108.76M | $106.36M | $102.92M | $99.67M | $96.63M | $94.17M | $91.75M | $96.50M |
| Total liabilities | $167.58M | $168.27M | $168.06M | $161.69M | $165.10M | $164.56M | $168.93M | $162.07M |
| Shareholders' equity | $501.84M | $482.17M | $500.00M | $522.81M | $497.04M | $517.13M | $535.51M | $559.75M |
| Net debt | $37.45M | $57.56M | $35.30M | $14.17M | $36.19M | $17.41M | -$3.10M | -$19.46M |
| Cash flow statement | ||||||||
| Operating cash flow | -$16.28M | -$16.25M | -$16.45M | -$14.29M | -$13.89M | -$15.47M | -$16.81M | -$18.20M |
| Investing cash flow | $16,000 | $27,000 | -$34,000 | -$203,000 | -$47,000 | -$56,000 | -$30,000 | -$99,000 |
| Financing cash flow | $38.76M | -$2.54M | -$2.01M | $40.30M | -$2.22M | -$2.57M | -$4.34M | -$2.15M |
| Depreciation & amortization | $927,000 | $990,000 | $1.08M | $1.10M | $1.07M | $1.11M | $1.10M | $1.09M |
| Stock-based compensation | $1.11M | $791,000 | $1.41M | $350,000 | $1.09M | $1.89M | $1.48M | $1.08M |
Free plan shows the latest 8 periods; Pro shows all 23 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.